Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma
Clinical trial NCT05243693 · UNKNOWN
Trial details
- NCT number
- NCT05243693
- Sponsor
- National Cancer Center, Korea
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-01
- Primary completion
- 2024-02-28
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.